Abstract
Primary pulmonary hypertension (PPH) is a fatal disease causing progressive right heart failure within three years of diagnosis.
1 Impairment of vascular and endothelial homeostasis is evidenced by a reduced synthesis of prostacyclin, increased thromboxane production, decreased formation of nitric oxide, and increased synthesis of endothelin-1. 2 3 Prostacyclins such as epoprostenol, a potent vasodilator and inhibitor of both platelet aggregation and smooth muscle cell proliferation, are eVective in the treatment of PPH. Although stereochemically diVerent, the prostacyclin analogue iloprost and epoprostenol act via a prostacyclin receptor present in pulmonary artery smooth muscle cells. 4 Pharmacokinetically, iloprost is more stable than epoprostenol with half lives of 30 minutes and 2 minutes, respectively. Both substances have been shown to improve pulmonary haemodynamics and survival in PPH when administered intravenously. 5 The continuous intravenous administration of epoprostenol is associated with therapeutic problems such as systemic hypotension, catheter sepsis, gastrointestinal upsets, jaw pain, and headache. We have shown that epoprostenol treatment reverts initial nonresponsiveness to nitric oxide (NO), 6 which suggests that pulmonary vasodilation may be incomplete in patients with PPH during treatment with epoprostenol. We have therefore examined whether additional inhalation of iloprost improves the pulmonary haemodynamics during continuous infusion of epoprostenol, given in a moderate to medium dose, in patients with stable PPH with side eVects to the epoprostenol treatment such as systemic hypotension and severe headache.
Methods

PATIENTS
Eight patients with PPH were investigated after a mean treatment period with epoprostenol (Flolan, GlaxoWellcome Ltd, Uxbridge, UK) of 18 months (range 4-28 months). Epoprostenol had been given as a result of nonresponsiveness to acute testing with NO (table  1) . Each patient gave written informed consent to participate in the study which was approved by the ethical committee of the University of Vienna. The diagnosis of PPH was based on a raised MPAP of >30 mm Hg and the diagnostic criteria published by Rich et al. 7 In contrast to the initial lack of vasoreactivity to NO, after treatment with epoprostenol all patients had a positive vasodilator response to NO (>10%, 20 ppm NO). The patients had stable pulmonary haemodynamics, although maximum doses were not achieved due to adverse eVects such as systemic hypotension and severe headache.
Iloprost (Ilomedin, Schering AG, Berlin, Germany; 30 µg) was inhaled for 15 minutes via the MicroDrop Master Jet (MPV, Truma, Germany) using a particle size of 3 µm to provide alveolar deposition of the substance. Pulmonary haemodynamics and gas exchange were measured before and 15 minutes after inhalation of iloprost while permanently delivering epoprostenol into the subclavian vein as described previously 8 using a portable pump system (CADD-1, Pharmacia-Upjohn, Vienna, Austria). Right heart catheterisation was performed as previously reported. 6 STATISTICAL ANALYSIS Data were analysed descriptively using the IDV-Module Report 6.0.08 and statistically with the IDV-Module Testimate 5.2a. Baseline demographic and haemodynamic variables were recorded and are presented as mean (SD). Intraindividual comparison of the haemodynamic variables measured at baseline and after inhalation with iloprost was made using the two sided Wilcoxon U test for paired data. p values below 0.05 were considered statistically significant.
Results
The eVect of simultaneous inhalation of iloprost (30 µg within 15 minutes) on pulmonary haemodynamics was tested in eight patients (two men) with a proven diagnosis of PPH continuously receiving intravenous epoprostenol (dose range 12-30 ng/min/kg, mean 20 ng/min/kg) for a mean period of 18 months. Before inhalation of iloprost the mean (SD) pulmonary artery pressure (MPAP) was 63 
Discussion
The combination of continuous intravenous treatment with epoprostenol and a 15 minute 
